Ironwood Pharmaceuticals Inc. (IRWD)
IRWD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.59
-4.52% on the day
Market cap
$593.2M
Small cap
Revenue · 2025
$296.2M
-15.7% on 2024
Net income · 2025
$24.0M
8.1% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | IRWD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2010 |
| SEC CIK | 0001446847 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $296.2M |
| Net income | $24.0M |
| Operating income | $98.5M |
| Net margin | 8.1% |
| Operating margin | 33.3% |
| Revenue growth | -15.7% |
| Cash | $215.5M |
| Total assets | $396.9M |
| P/E (computed) | 24.7× |
| P/S (computed) | 2.0× |
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.7% |
| 1 month | -11.1% |
| 3 months | -6.7% |
| Year to date | +7.1% |
| 1 year | +143.9% |
| From 52-week high | -33.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLYM | Climb Bio Inc. | $10.31 | -4.80% | $592.2M |
| NVCT | Nuvectis Pharma Inc. | $18.15 | -7.82% | $591.9M |
| AQST | Aquestive Therapeutics Inc. | $4.67 | -2.91% | $586.1M |
| CRMD | CorMedix Inc. | $7.39 | -0.94% | $576.0M |
| DSGN | Design Therapeutics Inc. | $9.78 | -10.36% | $612.0M |
| OLMA | Olema Pharmaceuticals Inc. | $7.02 | -4.62% | $614.2M |
| ZVRA | Zevra Therapeutics Inc. | $10.39 | -8.22% | $617.0M |
| WVE | Wave Life Sciences Inc. | $3.14 | -4.27% | $618.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier